We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Siga Technologies Inc (SIGA) Common Stock USD0.0001

Sell:$6.18 Buy:$6.21 Change: $0.1 (1.58%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
Change: $0.1 (1.58%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
Change: $0.1 (1.58%)
Market closed |  Prices as at close on 27 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The Company does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. It uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMO, Albemarle Corporation; Powdersize, LLC; Catalent Pharma Solutions LLC; and Packaging Coordinators, LLC.

Contact details

31 E 62nd St
United States
+1 (212) 6729100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$467.67 million
Shares in issue:
74.12 million
United States
US dollar

Key personnel

  • Phillip Gomez
    Chief Executive Officer, Director
  • Daniel Luckshire
    Chief Financial Officer, Executive Vice President, Secretary
  • Robin Abrams
    Chief Administrative Officer, General Counsel
  • Dennis Hruby
    Chief Scientific Officer, Vice President

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.